Clinical Trial Update: A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study of AC-201 controlled-release tablet in patients with hemophilic arthropathy completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilic Arthropathy

Drugs mentioned

• AC-201

Snippet

Sponsor: TWi Biotechnology, Inc. | Conditions: Hemophilic Arthropathy | Phase 2 | Status: COMPLETED